Euroapi S.A. EAPI.PA · Stock Open Euroapi S.A. in new tab
Euroapi S.A. Analysis (EAPI.PA)
Is Euroapi S.A. a good investment? Euroapi S.A. (EAPI.PA) is currently trading at 1.27 EUR. Market analysts have a consensus price target of 1.76 EUR. This suggests a potential upside from current levels.
Earnings Schedule: Euroapi S.A. is expected to release its next earnings report on July 28, 2026. The market consensus estimate for Forward EPS is -0.19.
Investor FAQ
Does Euroapi S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Euroapi S.A.?
Euroapi S.A. is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be July 28, 2026. The company currently has a trailing EPS of -2.23.
Company Profile
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization. The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
Community Discussion